These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Doctors have begun noticing a trend: they all seem to get full before finishing dinner, and it's likely thanks to drugs like ...

Reports link GLP-1 medications like Ozempic and Mounjaro to vision loss, prompting concerns over their safety.

利拉鲁肽注射剂的仿制药获批将有助于增加患者获得 2 型糖尿病治疗的机会。利拉鲁肽注射剂目前处于短缺状态。 美国食品药品管理局（FDA）批准了首个仿制药Victoza（利拉鲁肽注射液）18毫克/3毫升，这是一种胰高血糖素样肽-1（GLP-1）受体激动剂 ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

Researchers looked at the nine people who had vision problems while using the drugs and is one of several that have ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...